Biotech RadarJobs updated

COMPANY

Matrix Biomed

HQ: Irvine, CA source · matrixbiomed.com ↗ · West Coast

Clinical Phase 2

Location: Irvine, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Mucositis Nephrotoxicity Ototoxicity Ataxia Telangiectasia Louis-Bar Ataxia Telangiectasia Prostate Cancer Recurrent Biochemical Recurrent Prostate Cancer Glioblastoma Glioblastoma Multiforme Prostate Cancer Tempol MBM-02 MBM-01 MBM-02 (Tempol)

6Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia source ↗
  2. Trial start Phase 2: MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) source ↗
  3. Trial start Phase 2: MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer source ↗
  4. Trial start Phase 2: Treatment of Radiation and Cisplatin Induced Toxicities with Tempol source ↗

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT03480971Treatment of Radiation and Cisplatin Induced Toxicities with TempolPhase 2RecruitingMay 13, 20192025-07 (estimated)
NCT05491928Treatment of Metastatic Cancer in Terminally Diagnosed PatientsNot listedAvailableNot listedNot listed
NCT04887311MBM-01 (Tempol) for the Treatment of Ataxia TelangiectasiaPhase 2Unknown status (ClinicalTrials.gov)2021-072022-06 (estimated)
NCT04876755MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate CancerPhase 2Unknown status (ClinicalTrials.gov)May 30, 20212022-09 (estimated)
NCT04874506MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)Phase 2Unknown status (ClinicalTrials.gov)Jun 1, 20212023-01 (estimated)
NCT04337099A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate CancerNot listedAvailableNot listedNot listed
Feedback